KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

KYTRIL 3 MG / 3 ML INJECTION

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

3 MG / 3 ML

 

GENERIC NAME:

GRANISETRON

 

MANUFACTURER:

SMITH & NEPHEW LTD.

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

B

 

INDICATIONS:

Nausea, postoperative

Nausea, secondary to cancer chemotherapy

Vomiting, postoperative

Vomiting, secondary to cancer chemotherapy

 

SIDE EFFECTS:

Fever

Arrhythmias

chest pain

fainting

hypersensitivity reaction

Abdominal pain

constipation

diarrhea

headache

unusual tiredness or weakness

Agitation

dizziness

drowsiness

dyspepsia

insomnia

unusual taste in mouth

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

 

ADULT DOSE:

Nausea and vomiting, cancer chemotherapy-induced, prophylaxis; or [ Nausea and vomiting, cancer radiotherapy-induced, prophylaxis] - Intravenous, 10 mcg (base) per kg of body weight, administered within thirty minutes before initiation of emetogenic chemotherapy or radiotherapy. The dose may be administered undiluted over thirty seconds, or diluted with 5% dextrose injection or 0.9% sodium chloride injection and infused over five minutes. (See Preparation of dosage form .) Note: Dosage adjustment is not required in the elderly, or in patients with hepatic or renal function impairment.

 

MAXIMUM ADULT DOSE:

 

PEDIATRIC DOSE:

Children up to 2 years of age-Dosage has not been established. Children 2 years of age and older-See Usual adult and adolescent dose. 

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Nausea and vomiting, cancer chemotherapy-induced, prophylaxis; or [ Nausea and vomiting, cancer radiotherapy-induced, prophylaxis] - Intravenous, 10 mcg (base) per kg of body weight, administered within thirty minutes before initiation of emetogenic chemotherapy or radiotherapy. The dose may be administered undiluted over thirty seconds, or diluted with 5% dextrose injection or 0.9% sodium chloride injection and infused over five minutes. (See Preparation of dosage form .) Note: Dosage adjustment is not required in the elderly, or in patients with hepatic or renal function impairment.

 

 

PREVIOUS

  

NEXT